• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMD Millipore launches cancer stem cell ID kit

EMD Millipore launches cancer stem cell ID kit

November 9, 2015
CenterWatch Staff

EMD Millipore, the life science business of Merck of Darmstadt, Germany, has introduced the new AldeRed ALDH Detection Kit for identifying and isolating cancer stem cells.

EMD Millipore has entered into an exclusive license with Johns Hopkins University (JHU) to commercialize an innovative tool that provides cancer and stem cell scientists with new capabilities for live cell isolation and characterization. The AldeRed reagent is used to label cancer stem cells with a red fluorescent dye, making it possible to distinguish cancer stem cells in live cell populations where specific identification was previously impossible.

ALDH, a cancer stem cell marker enzyme, causes the AldeRed reagent to fluoresce in the far-red spectrum, allowing the cells to be identified and isolated with concurrent use of green fluorescent cell lines, transgenic animals and reporter assays. Previous ALDH reporters exhibited green fluorescence, which made it difficult to identify positive cells in an otherwise green fluorescent background.

“To support the search for cancer's cure, it is EMD Millipore’s responsibility to seek the most innovative technologies being developed by groundbreaking researchers and make these tools accessible to scientists globally,” said Udit Batra, president and CEO of EMD Millipore. “Our agreement with Johns Hopkins University to commercialize the AldeRed technology is an exciting step toward fulfilling that possibility.”

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing